Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. CytoDyn Inc (CYDY) Message Board

Penicillin & Leronlimab: From Science direct:

Message Board Public Reply | Private Reply | Keep | Replies (0)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 154563
(Total Views: 638)
Posted On: 04/04/2025 8:10:33 PM
Posted By: My69z
Penicillin & Leronlimab:

From Science direct:
In the United States, it has been estimated that 500 to 1000 deaths per year are secondary to penicillin-induced anaphylaxis

Google:
Anaphylaxis is a severe, potentially life-threatening allergic reaction that can develop rapidly.
It is also known as anaphylactic shock.

Google:
In 2022, there were approximately 53.2 million penicillin prescriptions in the United States, translating to a rate of 159 prescriptions per 1,000 people.

Google:
A study published in the National Institutes of Health (NIH) found that animals were infused intravenously with two mAbs at 25 mg/kg each, either leronlimab-PLS (Group 1) or leronlimab-WT (Group 2); both groups received the control anti-DSP mAb.

According to the National Institutes of Health (NIH) (.gov) animals were pre-treated with a control anti-DSP mAb to reduce the risk of anaphylactic reactions.

That is from our FcRn abstract under:
Selection of the control rhesus anti-desipramine mAb:

To account for the intrinsic differences between individual animals both within and between the groups, we co-administered the rhesus anti-desipramine (DSP) mAb, denoted ‘control mAb’, at the same time as the therapeutic leronlimab mAbs.

We have built-in anti an deadly side effects trigger, that Penicillin can cause. Of course we're not going to compete with aspirin or Penicillin, just looking at death rates per say while we wait.

So we have the 2 drugs that are known as super safe, can trigger deaths, & to the other extreme of :

Leronlimab treating Hiv & the most aggressive of deadly cancers, with so far 1600 patients across wide range of different disease trials, & no reported deaths.

What a surprise.....wow!!


(2)
(0)




CytoDyn Inc (CYDY) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  






Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us